Nitro Oleic Acid PPAR-gamma Agonist for Diabetes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for type-2 diabetes, such as PPAR-γ agonists like Rosiglitazone, often lead to side effects like weight gain and fluid retention, and there is a lack of understanding about the structural and biochemical determinants for modulating PPAR-γ activity, limiting the design of effective pharmacophores.
Innovation Solution
The use of nitro oleic acid and its metabolites as active agents, which act as potent agonists of PPAR-γ, improving insulin sensitivity and lowering blood glucose levels without weight gain, through specific binding interactions and metabolic conversion, offering a pharmaceutical composition for administration and monitoring of treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PPAR-γ agonists like Rosiglitazone are used to treat type-2 diabetes, then blood glucose levels are reduced and insulin sensitivity is improved, but weight gain and fluid retention occur as side effects
Solution Approach 1:
The patent modifies the chemical structure of known PPAR-γ agonists by introducing nitro groups at specific positions (9-nitro, 10-nitro, 12-nitro, or 13-nitro) on the fatty acid chain. This structural parameter change creates novel compounds that maintain PPAR-γ agonist activity while reducing or eliminating the weight gain and fluid retention side effects associated with conventional agents like Rosiglitazone
Solution Approach 2:
The invention applies local quality modification by specifically nitrating the fatty acid chain at particular positions rather than modifying the entire molecule uniformly. The nitro group introduction at specific locations (9-, 10-, 12-, or 13-position) creates localized structural changes that selectively modulate PPAR-γ activation while minimizing adverse effects on metabolic pathways leading to weight gain and fluid retention
2Adaptability or versatility
If there is a lack of understanding about structural and biochemical determinants for modulating PPAR-γ activity, then the design of effective pharmacophores is limited, but systematic approaches for pharmacophore design are needed
Solution Approach 1:
The patent segments the fatty acid structure into specific regions by introducing nitro groups at defined positions (9-, 10-, 12-, or 13-carbon positions). This segmentation approach allows systematic investigation of how local structural modifications affect PPAR-γ binding and activation, thereby generating knowledge about structure-activity relationships that can guide future pharmacophore design
Solution Approach 2:
The nitro fatty acid compounds serve as intermediaries between the known PPAR-γ agonist activity and the desired therapeutic effect without adverse side effects. These compounds mediate the interaction between the drug molecule and the PPAR-γ receptor, providing a bridge that allows researchers to study and understand the structural determinants of PPAR-γ modulation while achieving therapeutic benefits
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Nitro oleic acid effectively reduces blood glucose levels and improves insulin sensitivity in diabetic mice models without the side effects associated with existing PPAR-γ agonists, providing a promising therapeutic approach for type-2 diabetes with minimal weight gain and fluid retention.
Implementation Method 1
The signaling ability of nitro fatty acids stems predominantly from their ability to form reversible covalent adducts with nucleophilic centers of cellular proteins that are implicated in various transcriptional and cellular signaling processes. In particular, regulation of signaling activity most often occurs via the covalent modification of an active site thiol group of a protein target.
Implementation Method 2
nitro oleic acid and its metabolites as active agents, which act as potent agonists of PPAR-γ
Data Source
AI summary
Nitro oleic acid and related metabolites are agonists of PPAR-γ. Surprisingly, nitro oleic acid is a more potent agonist of PPAR-γ, relative to nitro linoleic acid. Thus, nitro oleic acid and its metabolites, as well as their pharmaceutically acceptable salts and prodrug forms, are candidate therapeutics for the treatment of type-2 diabetes, which results from insulin resistance accompanying the improper functioning of PPAR-γ.